Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with pointcheck: a portable non-invasive neutropenia analyzer
Ended Project Grant Awarded Last action
- Award ID
- R43CA228920
- Recipient
-
Leuko Labs, Inc. UEI T7SWKPALXK88
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $268,919
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date
- Originally
- Place of performance
- Cambridge, MA 02139, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $55,000 | |
| Original award | $213,919 |
Quick answers
Who received award R43CA228920?
R43CA228920 was awarded to Leuko Labs, Inc. by National Cancer Institute (National Institutes of Health) on July 12, 2018.
How much is award R43CA228920 worth?
$268,919 has been obligated on R43CA228920.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award